Loading
Life sciences · Journal article
Current Oncology · October 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
For advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, targeted therapy is the standard first-line treatment, but acquired resistance and disease progression are inevitable. Identification of resistance mechanisms is crucial for guiding subsequent anti-tumor therapy. We report a 57-year-old female patient with advanced lung adenocarcinoma harboring an EGFR exon 21 L858R mutation. The patient experienced disease progression with rare gynecological metastasis after 16 months of first-line furmonertinib therapy. Next-generation sequencing (NGS) of the uterine metastatic lesion identified concurrence of EGFR mutation and ALK fusion, while fluorescence in situ hybridization (FISH) confirmed MET polysomy. The patient exhibited intolerance to the combination therapy of glumetinib plus furmonertinib. Subsequently, the patient received a combination of furmonertinib and the ALK-TKI ensartinib, which was assessed as a partial response (PR) at the first restaging evaluation (1 month after treatment initiation), with favorable safety and tolerability. Secondary ALK fusion may represent a rare but clinically meaningful resistance mechanism in EGFR-mutant NSCLC. Furthermore, while gynecological metastasis from lung cancer is uncommon, clinicians should be alert to this possibility in patients presenting with relevant symptoms, with pelvic examination conducted as needed.